Company: RCUS
Filing Date: 2025-10-31
Form Type: 424B5
Source: 0001193125-25-260836
Chunk: 13

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-31
Form: 424B5
Chunk 13
---
 | our expectations regarding the uses of the net proceeds from the sale of our common stock in this offering; |

| • |     | our expectations regarding the timing and achievement of our investigational product development activities and                                                                            
 ongoing and planned clinical trials, including initiation of new clinical trials, completion of enrollment and availability and timing for reporting of data from ongoing clinical trials; |

| • |     | our ability to develop intra-portfolio combinations and highly-differentiated small-molecule investigational                                          
 products, including our ability to create small-molecule investigational products with ideal pharmacological properties and desired clinical effects; |

| • |     | our expectations regarding the efficiency and speed with which we can create and advance small-molecule 
 investigational products and develop our investigational products and combination therapies;            |

| • |     | our reliance on third parties to conduct our ongoing and future clinical trials and third-party manufacturers to 
 manufacture and supply our investigational products;                                                             |

| • |     | our expectations regarding the nature of the immuno-oncology pathways we are targeting, the size of the potential 
 patient population and the potential market size;                                                                 |

| • |     | our ability to obtain and maintain control of our combination investigational products and maximize the 
 commercial potential of our investigational products;                                                   |

| • |     | our ability to obtain and maintain regulatory approvals of our investigational products and the potential market 
 opportunities for commercializing our investigational products;                                                  |

| • |     | our ability to retain and recruit key personnel, estimates of our expenses, future revenue, capital requirements 
 and our needs for additional financing;                                                                          |

| • |     | our ability to develop, acquire and advance investigational products into, and successfully complete, clinical 
 trials;                                                                                                        |

| • |     | our initiation, scope, design, timing, progress and results of future research and development programs, 
 preclinical studies and clinical trials;                                                                 |

| • |     | our ability to obtain and maintain intellectual property rights covering our investigational products; |

| • |     | our expectations regarding the developments and projections relating to our competitors; |

| • |     | our expectations regarding our industry; and |

| • |     | our expectations as to the effect that geopolitical instability and public health outbreaks will have on our 
 company.                                                                                                     |

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “